Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer.

ABSTRACT:

Introduction

An emerging challenge in early breast cancer (eBC) is improving risk assessment through the use of biomarkers. Clinical guidelines have recommended urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1. This study aimed to validate the prognostic and predictive impact of uPA/PAI-1.

Patients and methods

From a prospective cohort of 1270 patients (PiA-study, Prognostic assessment in routine Application, NCT01592825), concentrations of uPA and PAI-1 were determined in fresh tumor tissue (n = 813) by ELISA (FEMTELLE®; LOXO Diagnostics). The uPA/PAI-1 status was defined as low if both uPA and PAI-1 levels were low and as high if one or both were elevated. Primary objectives were the distribution of the uPA/PAI-1 status and its association with clinical/h

SUBMITTER: Wieder V 

PROVIDER: S-EPMC12686101 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature